Affimed lays off around 50 staffers as it brings combo NK cell therapy to PhII
Affimed on Tuesday announced that it had laid off a quarter of its staff, or roughly 50 people, in April, joining a slew of other biotech companies that have let employees go over the past year.
The German NK cell biotech said the layoffs were needed to help fund three clinical programs that are currently in early-stage studies. “The bulk of the reductions have therefore come from other areas of the organization – discovery, preclinical, and some administrative roles,” an Affimed spokesperson told Endpoints News in an email.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters